Results 81 to 90 of about 101,617 (297)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Comparison of safety profiles of DPP-4 inhibitors with SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review [PDF]

In type 2 diabetes mellitus (T2DM), add-on therapy to metformin is often required. Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used, but differ in their safety profiles due to distinct ...
Patel, Ankit N., Nimavat, Zeel R., Gor, Alpa P., Ganguly, Barna   +3 more
core   +2 more sources

Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus [PDF]

, 2019
Achieving and maintaining recommended glycemic targets without causing adverse e ffects, including hypoglycemia, is challenging, especially in older patients with type 2 diabetes mellitus (T2DM).
Daniele, Giuseppe, Croci M, Avogaro A., Invitti C., Croci, Marina, Formichi C., Orsi, Emanuela, Sesti G, Frontoni S, Purrello F., Avogaro, Angelo, Resi, Veronica, Dotta F, Sesti G., Dauriz M., Dotta F., Formichi, Caterina, Picconi F., Frontoni S., Purrello, Francesco, Bonora, Enzo, Bonora E, Picconi, Fabiana, Dotta, Francesco, Invitti, Cecilia, Orsi E., Belcastro S, Resi V, Frontoni, Simona, Picconi F, Belcastro S., Resi V., Dauriz M, Orsi E, Daniele G, Bonora B. M., Sesti, Giorgio, Daniele G., Croci M., Belcastro, Sara, Bonora, Benedetta Maria, Dauriz, Marco, Avogaro A, Formichi C, Bonora E., Invitti C, Bonora BM   +46 more
core   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Association of dipeptidyl peptidase-4 inhibitor and recurrent pancreatitis risk among patients with type 2 diabetes: A retrospective cohort study

Frontiers in Pharmacology
Introduction: Following the introduction of incretin-based drugs to the market, instances of acute pancreatitis have been reported, leading the FDA to mandate a warning label. Incretin-based therapy has been linked to a rare yet significant adverse event
Yi-Sun Yang, Yi-Sun Yang, Edy Kornelius, Edy Kornelius, Yu-Hsun Wang, Shih-Chan Lo, Shih-Chan Lo, Chien-Ning Huang, Chien-Ning Huang   +8 more
doaj   +1 more source

New Trends In The Treatment Of Diabetes Mellitus Type 2 [PDF]

, 2019
It's about the new oral antidiabetic medications, the ones acting through the incretin pathway like the DPP-4 Inhibitors and GLP-1 analogues and the ones acting on the kidneys like the SGLT-2 inhibitors.
Yusuf, Fatima Kabiru
core  

Cisplatin nephrotoxicity in user or non-user of DPP-4 inhibitors. [PDF]

, 2020
Cisplatin nephrotoxicity in user or non-user of DPP-4 inhibitors.
Kento Ishibuchi (8478558), Ryuichi Furuya (710369), Hideo Yasuda (710367), Hirotaka Fukasawa (168260), Atsushi Kitamura (1993150), Takamasa Iwakura (798461)   +5 more
core   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus

Journal of Diabetes Research, 2013
Objective. To review the current literature investigating the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk factors of cardiovascular disease (CVD). Methods.
Pegah Yousefzadeh, Xiangbing Wang
doaj   +1 more source

Atomically precise metal cluster enzymes for pathological tissue regeneration

BMEMat, EarlyView.
Schematic illustration of atomically precise metal cluster enzymes (MCEs) for pathological tissue regeneration. Atomically precise MCEs can modulate biological processes, such as attenuation of inflammatory responses, eradication of bacterial pathogens, regulation of angiogenesis, and promotion of cell development.
Ziqiang Xiong, Zhifeng Shi, Mengqing Li, Jien Han, Haoyan Chen, Maofei Ran, Shaojian Zhong, Limin Ma, Chengyun Ning, Youzhun Fan, Zhenghua Tang, Peng Yu   +11 more
wiley   +1 more source